500,000 Shares in Alto Neuroscience, Inc. $ANRO Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC acquired a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 500,000 shares of the company’s stock, valued at approximately $11,240,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ANRO. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the fourth quarter worth about $62,000. XTX Topco Ltd increased its stake in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the period. Renaissance Technologies LLC raised its holdings in Alto Neuroscience by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after buying an additional 6,100 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Alto Neuroscience by 26.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after buying an additional 8,148 shares during the period. Finally, AlphaCore Capital LLC boosted its position in Alto Neuroscience by 100.0% during the 4th quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after buying an additional 10,000 shares during the period.

Alto Neuroscience Price Performance

NYSE:ANRO opened at $26.72 on Friday. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The business’s 50-day simple moving average is $23.47 and its two-hundred day simple moving average is $21.50. The stock has a market cap of $937.53 million, a PE ratio of -11.04 and a beta of 1.04. Alto Neuroscience, Inc. has a 52 week low of $3.00 and a 52 week high of $28.85.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, analysts forecast that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on ANRO. Robert W. Baird cut their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. JonesTrading reduced their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Wall Street Zen raised shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.